- Home
- ATRA
as 11-21-2024 11:31am EST
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | THOUSAND OAKS |
| Market Cap: | 50.3M | IPO Year: | 2014 |
| Target Price: | $26.88 | AVG Volume (30 days): | 142.2K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -22.60 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.50 - $39.50 | Next Earning Date: | 11-12-2024 |
| Revenue: | $100,439,000 | Revenue Growth: | 2111.34% |
| Revenue Growth (this year): | 1190.8% | Revenue Growth (next year): | -3.38% |
Stock Insider Trading Activity of Atara Biotherapeutics Inc. (ATRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Henrich Jill | ATRA | EVP, Chief Regulatory Officer | Nov 18 '24 | Sell | $11.20 | 1,000 | $11,198.00 | 19,378 | |
| Nguyen AnhCo | ATRA | President and CEO | Nov 18 '24 | Sell | $11.20 | 1,664 | $18,633.47 | 77,454 |
Latest Atara Biotherapeutics Inc. News
ATRA Breaking Stock News: Dive into ATRA Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations
Business Wire
8 days ago
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
Zacks
9 days ago
Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
9 days ago
Atara Biotherapeutics: Q3 Earnings Snapshot
Business Wire
9 days ago
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress
Business Wire
16 days ago
Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Zacks
a month ago
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know
Business Wire
2 months ago
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Compare ATRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ATRA Atara Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.